Pharmacy managers inflated drug prices by $7.3 billion

FTC: ‘Big 3’ Pharmacy Benefit Managers Engaged in Price Gouging
FTC: ‘Big 3’ Pharmacy Benefit Managers Engaged in Price Gouging, PBMs, UnitedHealth OptumRx, CVS Caremark Rx, Express Scripts
FTC report shows $7.3 billion in drug price inflation by leading pharmacy benefit managers
From 2017 to 2022, the companies marked up prices at their pharmacies by hundreds or thousands of percent, netting them $7.3 billion in revenue.
US FTC finds major pharmacy benefit managers inflated drug prices for $7.3 billion gain
The nation's three largest pharmacy benefit managers have significantly marked up the prices of certain medicines, including for heart disease, cancer and HIV, at their affiliated pharmacies, the U.S.
FTC finds middlemen inflate specialty generic drug prices by billions of dollars
Pharmacy benefit managers, which serve as the middlemen between drug makers, insurers and pharmacies, reaped $7.3 billion in revenue from marking up the prices of dozens of specialty generic drugs between 2017 and 2022,
Another FTC report is highly critical of pharmacy benefit managers
In the debate over the high cost of prescription drugs, pharmacy benefit managers are hotly contested. PBMs, the middlemen in many prescription drug transa
Largest Pharmacy-Benefit Managers Hiked Up Drug Prices, FTC Says
The largest pharmacy-benefit managers hiked the prices of certain drugs dispensed through their own pharmacies, according to a new report by the Federal Trade Commission released on Tuesday. The markups helped the PBMs reap $7.
FTC releases second report slamming pharmacy benefit managers
Agency commissioners voted unanimously on Tuesday to publish the report, which makes similar allegations against the controversial drug middlemen as the agency’s first report released last summer — but relies on more data.
FTC releases new findings in drug price inflation investigation
A new report from the Federal Trade Commission is uncovering what appears to be a major driver of the high cost of prescription drugs.
PBMs made billions marking up specialty drugs by more than 1,000 percent: FTC
The Federal Trade Commission (FTC) on Tuesday released its second interim report on pharmacy benefit managers (PBM), saying the major industry middlemen generate billions in revenue through vertical integration,
Top three insurers reaped $7.3 billion through their drug middlemen's markups, FTC says
Regulators published their most detailed findings yet on how some of the nation’s largest companies profited from "excess" ...
MedCity News14h
Healthcare Leaders Support FTC’s Second Report on PBMs, While PBMs Criticize Findings
On Tuesday, the Federal Trade Commission released its second interim staff report on prescription drug middlemen. The report ...
JD Supra1h
Jan. 14 - Likely the FTC’s Final Open Commission Meeting
Lina Khan chaired what was likely the final open commission meeting of her time as chair of the Federal Trade Commission (FTC) and ...
policymed.com1d
Second Federal Trade Commission Report on Pharmacy Benefit Managers (PBM’s) Focuses on Specialty Generics
The Federal Trade Commission (FTC) released its second interim staff report “Specialty Generic Drugs a Growing Profit Center ...